PDF Publication Title:
Text from PDF Page: 020
Materials 2020, 13, 2646 20 of 24 Supplementary Materials: The following are available online at http://www.mdpi.com/1996-1944/13/11/2646/s1, Figure S1: 1H NMR spectrum of compound 5 (600 MHz, CDCl3, ppm). Residual solvent peaks: *Et2O, **CH3OH.; Figure S2: 13C NMR spectrum of compound 5 (150.90 MHz, CDCl3, ppm). Residual solvent peak: *Et2O.; Figure S3: HRESI-TOFMS spectrum of compound 5.; Figure S4: 1H NMR spectrum of dye 9 (600 MHz, CDCl3, ppm). Residual solvent peak: *CH3OH.; Figure S5: 13C NMR spectrum of dye 9 (150.9 MHz, CDCl3, ppm); Figure S6: HRESI-TOFMS spectrum of dye 9.; Figure S7: 1H NMR spectrum of dye 10 (400 MHz, CDCl3, ppm). Residual solvent peaks: *CH2Cl2, **CH3OH.; Figure S8: 13C NMR spectrum of dye 10 (150.9 MHz, CDCl3, ppm). Residual solvent peaks: *Et2O, **CH2Cl2.; Figure S9: LRESI-TOFMS spectrum of dye 10.; Figure S10: 1H NMR spectrum of dye 11 (600 MHz, DMSO-d6, ppm); Figure S11: 13C NMR spectrum of dye 11 (150.9 MHz, DMSO-d6, ppm); Figure S12: LRESI-TOFMS spectrum of dye 11.; Figure S13: 1H NMR spectrum of dye 12 (600 MHz, DMSO-d6, ppm). Residual solvent peak: *CH2Cl2.; Figure S14: 13C NMR spectrum of dye 12 (150.9 MHz, DMSO-d6, ppm). Residual solvent peak: *CH2Cl2.; Figure S15: LRESI-TOFMS spectrum of dye 12. Author Contributions: Conceptualization, E.L., A.M.S. and L.V.R.; Formal analysis, E.L., A.M.S. and L.V.R.; Methodology, E.L., J.R.F., L.F.V.F., A.M.S. and L.V.R., Investigation, E.L., R.E.B., D.F., J.R.F., P.A., E.B.S., L.F.V.F.; Resources, R.E.B., P.A., J.R.F., E.B.S., L.F.V.F., A.M.S. and L.V.R.; Supervision, L.V.R. and A.M.S.; Visualization, E.L. and L.V.R.; Writing–original draft, E.L. and L.V.R.; Writing–review & editing, E.L., R.E.B., P.A., E.B.S., A.M.S. and L.V.R. All authors have read and agreed to the published version of the manuscript. Funding: This research was funded by the European Investment Funds by FEDER/COMPETE/POCI under projects POCI-01-0145-FEDER-006958 (CITAB) and POCI-01-0145-FEDER-007491 (CICS-UBI) and Funds by FCT—Portuguese Foundation for Science and technology, under the projects UIDB/ 04033/2020 (CITAB) and UIDB/ 00616/2020 (CQ-VR). This work was also supported by funds from the Health Sciences Research Center (CICS-UBI) through National Funds by FCT—Foundation for Science and Technology (UID/Multi/00709/2019). The research at iBB was supported by Project UID/NAN/50024/2019 and M-ERA-NET/0002/2015 from FCT. E.L. was supported by the FCT PhD grant SFRH/BD/147645/2019. Conflicts of Interest: The authors declare no conflict of interest. References 1. Torre, L.A.; Islami, F.; Siegel, R.L.; Ward, E.M.; Jemal, A. Global cancer in women: Burden and trends. Cancer Epidemiol. Biomark. Prev. 2017, 26, 444–457. [CrossRef] [PubMed] 2. Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018, 4, 1553–1568. [CrossRef] [PubMed] 3. Möller, S.; Mucci, L.A.; Harris, J.R.; Scheike, T.; Holst, K.; Halekoh, U.; Adami, H.-O.; Czene, K.; Christensen, K.; Holm, N.V.; et al. The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer. Cancer Epidemiol. Biomark. Prev. 2016, 25, 145–150. [CrossRef] 4. Stratton, M.R.; Rahman, N. The emerging landscape of breast cancer susceptibility. Nat. Genet. 2007, 40, 17–22. [CrossRef] [PubMed] 5. Lamberti, M.J.; Vittar, N.B.R.; Rivarola, V.A. Breast cancer as photodynamic therapy target: Enhanced therapeutic efficiency by overview of tumor complexity. World J. Clin. Oncol. 2014, 5, 901–907. [CrossRef] [PubMed] 6. Sun, Y.-S.; Zhao, Z.; Yang, Z.-N.; Xu, F.; Lu, H.-J.; Zhu, Z.-Y.; Shi, W.; Jiang, J.; Yao, P.-P.; Zhu, H.-P. Risk Factors and Preventions of Breast Cancer. Int. J. Boil. Sci. 2017, 13, 1387–1397. [CrossRef] [PubMed] 7. Akram, M.; Iqbal, M.; Daniyal, M.; Khan, A.U. Awareness and current knowledge of breast cancer. Biol. Res. 2017, 50, 33. [CrossRef] [PubMed] 8. Abdel-Kader, M.H. Chapter 1. The Journey of PDT throughout History: PDT from Pharos to Present. In Photodynamic Medicine: From Bench to Clinic; Royal Society of Chemistry (RCS): London, UK, 2016; pp. 1–21. 9. Dolmans, D.E.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3, 380–387. [CrossRef] [PubMed] 10. Allison, R.R.; Moghissi, K. Oncologic photodynamic therapy: Clinical strategies that modulate mechanisms of action. Photodiagn. Photodyn. Ther. 2013, 10, 331–341. [CrossRef] [PubMed] 11. Newman, D.K. Photodynamic therapy: Current role in the treatment of chorioretinal conditions. Eye 2016, 30, 202–210. [CrossRef] [PubMed] 12. Davis, R.K. Photodynamic therapy in otolaryngology-head and neck surgery. Otolaryngol. Clin. N. Am. 1990, 23, 107–119.PDF Image | Photophysicochemical Light Antiproliferative vs cancer
PDF Search Title:
Photophysicochemical Light Antiproliferative vs cancerOriginal File Name Searched:
materials-13-02646-v2.pdfDIY PDF Search: Google It | Yahoo | Bing
Cruise Ship Reviews | Luxury Resort | Jet | Yacht | and Travel Tech More Info
Cruising Review Topics and Articles More Info
Software based on Filemaker for the travel industry More Info
The Burgenstock Resort: Reviews on CruisingReview website... More Info
Resort Reviews: World Class resorts... More Info
The Riffelalp Resort: Reviews on CruisingReview website... More Info
CONTACT TEL: 608-238-6001 Email: greg@cruisingreview.com (Standard Web Page)